Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.
Inflamm Bowel Dis. 2013 Feb;19(2):342-9. doi: 10.1097/MIB.0b013e318286f771.
It is still unclear whether inflammatory bowel disease (IBD) patients with adenomas have a higher risk of developing high-grade dysplasia (HGD) or colorectal cancer (CRC) than non-IBD patients with sporadic adenomas. We compared the risk of advanced neoplasia (AN, defined as HGD or CRC) in IBD patients with adenomas to IBD patients without adenomas and patients without IBD with adenomas.
IBD patients with a histological adenoma diagnosis (IBD + adenoma), age-matched IBD patients without adenoma (IBD-nonadenoma), and adenoma patients without IBD (nonIBD + adenoma) were enrolled in this study. Medical charts were reviewed for adenoma characteristics and development of AN. The endoscopic appearance of the adenomas was characterized as typical (solitary sessile or pedunculated) or atypical (all other descriptions).
A total of 110 IBD + adenoma patients, 123 IBD-nonadenoma patients, and 179 nonIBD + adenoma patients were included. Mean duration of follow-up was 88 months (SD ±41). The 5-year cumulative risks of AN were 11%, 3%, and 5% in IBD + adenoma, IBD-nonadenoma, and nonIBD + adenoma patients, respectively (P < 0.01). In IBD patients atypical adenomas were associated with a higher 5-year cumulative risk of AN compared to IBD patients with typical adenomas (18% vs. 7%, P = 0.03).
IBD patients with a histological diagnosis of adenoma have a higher risk of developing AN than adenoma patients without IBD and IBD patients without adenomas. The presence of atypical adenomas in particular was associated with this increased risk, although patients with typical adenomas were found to carry an additional risk as well.
目前尚不清楚患有腺瘤的炎症性肠病(IBD)患者发生高级别异型增生(HGD)或结直肠癌(CRC)的风险是否高于非 IBD 伴散发性腺瘤患者。我们比较了伴有腺瘤的 IBD 患者、无腺瘤的 IBD 患者和无 IBD 伴腺瘤的患者发生高级别瘤变(AN,定义为 HGD 或 CRC)的风险。
本研究纳入了组织学诊断为腺瘤的 IBD 患者(IBD+腺瘤)、年龄匹配的无腺瘤的 IBD 患者(IBD-无腺瘤)和无 IBD 伴腺瘤的患者(非 IBD+腺瘤)。回顾性分析了腺瘤特征和 AN 发生情况。将腺瘤的内镜表现分为典型(单发无蒂或有蒂)或非典型(其他所有描述)。
共纳入 110 例 IBD+腺瘤患者、123 例 IBD-无腺瘤患者和 179 例非 IBD+腺瘤患者。中位随访时间为 88 个月(±41)。IBD+腺瘤、IBD-无腺瘤和非 IBD+腺瘤患者的 5 年 AN 累计发生率分别为 11%、3%和 5%(P<0.01)。在 IBD 患者中,非典型腺瘤与 5 年 AN 累计风险较高相关(18%比 7%,P=0.03),而与 IBD 患者具有典型腺瘤相比。
与非 IBD 伴腺瘤患者和无腺瘤的 IBD 患者相比,组织学诊断为腺瘤的 IBD 患者发生 AN 的风险更高。特别是存在非典型腺瘤与这种风险增加相关,尽管发现具有典型腺瘤的患者也存在额外的风险。